PGI18 Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C: Submission to the National Institute for Health and Clinical Excellence (NICE)

S.C Humphreys,Michaela Lion ,Elamin H Elbasha ,Shannon Ferrante ,Christopher O’regan

doi:10.1016/j.jval.2012.08.767

PGI18 Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C: Submission to the National Institute for Health and Clinical Excellence (NICE)

S.C Humphreys, Michaela Lion + Show 3 more

Open Access

https://doi.org/10.1016/j.jval.2012.08.767

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Nov 1, 2012
Citations: 3	License type: publisher-specific-oa

Affiliation: MSD (United Kingdom), MSD (United States)

#National Institute For Health And Clinical Excellence #Boceprevir In Combination + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PGI18 Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C: Submission to the National Institute for Health and Clinical Excellence (NICE)

Full Text